72P Cemiplimab monotherapy for first-line advanced NSCLC patients with PD-L1 expression ≥50%: 6-y outcomes of EMPOWER-Lung 1
was 61.5%; PFS was not mature.Efficacy was observed across PD-L1 levels in both NSQ and SQ NSCLC (Table ).Across 30 pts with NSCLC (NSQ and SQ), 40.0% reported Gr 3 treatment-related AEs (TRAEs) and 33.3% reported immune-related (irAEs) that were Gr 3 in 6.7%.TRAEs led to treatment discontinuation in 13.3% pts.No TEAEs resulted in death.The safety profile was comparable between NSQ and SQ NSCLC.Conclusions: Pumitamig showed preliminary antitumor activity across PD-L1 levels and acceptable safety in pts with advanced NSCLC, including SQ cell carcinoma.Pumitamig + chemo in pts with NSCLC is being further investigated in ongoing global studies including ROSETTA Lung-02 (NCT06712316) and BNT327-07 (NCT06841055).Clinical trial identification: NCT05918445.
Authors
- Igor Bondarenko (ORCID: https://orcid.org/0000-0002-7071-2471)
- Sue Chua
- Xiaoli Jia (ORCID: https://orcid.org/0000-0001-8865-9771)
- G.F. Ho
- Manika Kaul
- Saadettin Kilickap
- Y. Li
- Y. Kulyaba
- A. Sezer
- H. Magnan
- M. Ozguroglu
- M. Gogishvili
- M. Gumus
- M. Schenker
- Z.I. Kasimova
- R.I. Scheusan
- M.C. Garassino
- A. Baramidze
- M. Nechaeva
Institutions
- Regeneron (United States) (US)
- Başkent University (TR)
- University of Malaya (MY)
- University of Chicago (US)
- National Institute of Emergency Medicine "Pirogov" (BG)
- Istanbul University-Cerrahpaşa (TR)
- Istinye University (TR)
- Sociedade Brasileira de Oncologia Clínica (BR)
- International Institute of Management Arkhangelsk (RU)
- Istanbul Medeniyet University (TR)
- Dnipro State Medical University (UA)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106379
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00